Next Article in Journal
Contribution of Hypoxic Exercise Testing to Predict High-Altitude Pathology: A Systematic Review
Previous Article in Journal
A Comparative Study on the Viability of Normal and Cancerous Cells upon Irradiation with a Steady Beam of THz Rays
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Life
Volume 12
Issue 3
10.3390/life12030378
life-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

How to Treat HR+/HER2- Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story

by
Viola Cogliati
1,*,
Serena Capici
1,
Francesca Fulvia Pepe
1,
Pierluigi di Mauro
2,
Francesca Riva
2,
Federica Cicchiello
2,
Claudia Maggioni
2,
Nicoletta Cordani
3,
Maria Grazia Cerrito
3 and
Marina Elena Cazzaniga
1,3
1
Phase 1 Research Centre, ASST Monza, 20900 Monza, MB, Italy
2
Oncology Unit, ASST Monza, 20900 Monza, MB, Italy
3
School of Medicine and Surgery, University of Milano Bicocca, 20900 Monza, MB, Italy
*
Author to whom correspondence should be addressed.
Life 2022, 12(3), 378; https://doi.org/10.3390/life12030378
Submission received: 18 January 2022 / Revised: 26 February 2022 / Accepted: 3 March 2022 / Published: 5 March 2022
(This article belongs to the Section Cell Biology and Tissue Engineering)
Versions Notes

Abstract

CDK4/6 inhibitors in association with endocrine therapy represent the best therapeutic choice for either endocrine-sensitive or resistant hormone-receptor-positive advanced breast cancer patients. On the contrary, the optimal therapeutic strategy after the failure of CDK4/6 inhibitors-based treatment still remains an open question worldwide. In this review, we analyze the most studied mechanisms of resistance to CDK4/6 inhibitors treatment, as well as the most significant results of retrospective and prospective trials in the setting of progression after CDK4/6 inhibitors, to provide the reader a comprehensive overview from both a preclinical and especially a clinical perspective. In our opinion, an approach based on a deeper knowledge of resistance mechanisms to CDK4/6 inhibitors, but also on a careful analysis of what is done in clinical practice, can lead to a better definition of prospective randomized trials, to implement a personalized sequence approach, based on molecular analyses.
Keywords: metastatic breast cancer; CDK4/6 inhibitors; therapy resistance; treatment sequencing metastatic breast cancer; CDK4/6 inhibitors; therapy resistance; treatment sequencing

Share and Cite

MDPI and ACS Style

Cogliati, V.; Capici, S.; Pepe, F.F.; di Mauro, P.; Riva, F.; Cicchiello, F.; Maggioni, C.; Cordani, N.; Cerrito, M.G.; Cazzaniga, M.E. How to Treat HR+/HER2- Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story. Life 2022, 12, 378. https://doi.org/10.3390/life12030378

AMA Style

Cogliati V, Capici S, Pepe FF, di Mauro P, Riva F, Cicchiello F, Maggioni C, Cordani N, Cerrito MG, Cazzaniga ME. How to Treat HR+/HER2- Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story. Life. 2022; 12(3):378. https://doi.org/10.3390/life12030378

Chicago/Turabian Style

Cogliati, Viola, Serena Capici, Francesca Fulvia Pepe, Pierluigi di Mauro, Francesca Riva, Federica Cicchiello, Claudia Maggioni, Nicoletta Cordani, Maria Grazia Cerrito, and Marina Elena Cazzaniga. 2022. "How to Treat HR+/HER2- Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story" Life 12, no. 3: 378. https://doi.org/10.3390/life12030378

APA Style

Cogliati, V., Capici, S., Pepe, F. F., di Mauro, P., Riva, F., Cicchiello, F., Maggioni, C., Cordani, N., Cerrito, M. G., & Cazzaniga, M. E. (2022). How to Treat HR+/HER2- Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story. Life, 12(3), 378. https://doi.org/10.3390/life12030378

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop